)
)
Pharvaris Investor Relations Material
Latest events
Status Update
Pharvaris
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Pharvaris N.V.
Access all reports
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, particularly hereditary angioedema (HAE). The company specializes in creating oral bradykinin B2 receptor antagonists, offering alternatives to existing injected treatments. Its key developments include PHVS416, a soft capsule for on-demand use during acute HAE attacks, and PHVS719, an extended-release tablet aimed at preventing such attacks. Pharvaris operates primarily in the Netherlands, Switzerland, and the United States. The company is headquartered in Leiden, the Netherlands, and its shares are listed on the NASDAQ.
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
PHVS
Country
🇺🇸 United States